Northway Biotech
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The First $5M: Andreas Geldstrom from GENERALIFX Shares His AI-Powered Investment Strategies in an Exclusive Webinar13.3.2025 11:30:00 CET | Press release
Live Webinar on March 21st at 18:30 CET - Registration Now Open ZURICH, SWITZERLAND / ACCESS Newswire / March 13, 2025 / GENERALIFX, a leading provider of investment education, is set to host an exclusive live webinar featuring Andreas Geldstrom, a renowned financial strategist and AI-driven trading expert. The event, scheduled for March 21st at 18:30 CET, will reveal the key strategies that have helped traders achieve their first $5 million in profits using AI-powered investment techniques. As the financial industry continues to evolve, artificial intelligence is reshaping trading and investment strategies, enabling traders to identify market opportunities with greater accuracy and efficiency. GENERALIFX has been at the forefront of this revolution, equipping investors with the knowledge and tools needed to navigate the markets successfully. Webinar Highlights: The Role of AI in Trading: How machine learning is transforming market analysis and decision-making. Effective Risk Managemen
MicroVision To Announce Fourth Quarter and Full Year 2024 Results on March 26, 202512.3.2025 16:05:00 CET | Press release
REDMOND, WA / ACCESS Newswire / March 12, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announces that it will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025 after the market close. The Company will subsequently hold a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 1:30 PM PT/4:30 PM ET on Wednesday, March 26, 2025 to discuss the financial results and provide a business update. Analysts and investors may pose questions for management during the live webcast on March 26, 2025, and may submit questions HERE in advance of the conference call. The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab HERE. The webcast will be archived on the website for future viewing. About MicroVision MicroVision drives global
Curve Energy Corp. And Lot 49 Capital Corp. Sign Definitive Agreement for Amalgamation and TSX Venture Listing11.3.2025 18:35:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / March 11, 2025 / Curve Energy Corp. (the "Company" or "Curve") and Lot 49 Capital Corp. ("Lot 49") are pleased to announce that they have entered into a definitive agreement (the "Definitive Agreement") to combine the two companies (the "Transaction") which will constitute a reverse takeover transaction ("RTO") of Lot 49. The Transaction is structured to facilitate the listing of the combined entity on the TSX Venture Exchange ("TSXV"). The Transaction is expected to be completed by way of a three-cornered amalgamation under the provisions of the Business Corporations Act (British Columbia) whereby a wholly-owned subsidiary of Lot 49 ("SubCo"), will amalgamate with Curve. All of the issued and outstanding common shares of SubCo and Curve following the amalgamation will be immediately exchanged for common shares of Lot 49 ("Lot 49 Shares") on a one-for-one basis. In connection with closing of the Transaction, Lot 49 intends to settle approximately $138,
Bear Robotics' Carti 100 Wins iF DESIGN AWARD 2025, Setting New Standards in Logistics Automation11.3.2025 11:58:00 CET | Press release
REDWOOD CITY, CA / ACCESS Newswire / March 11, 2025 / Bear Robotics is thrilled to announce that its Carti 100 autonomous mobile robot has been awarded the prestigious iF DESIGN AWARD 2025 in the Product category, Robotics discipline. This achievement reinforces Bear Robotics' position as a leader in innovative robotic design for logistics, building upon the success of the Servi Plus award earlier last year. Carti 100 stood out among nearly 11,000 entries from 66 countries, impressing a panel of 131 international design experts. The iF DESIGN AWARD, recognized globally as a symbol of design excellence, underscores Bear Robotics' commitment to merging cutting-edge technology with user-centric design. Designed by Bear Robotics' in-house design and engineering teams in Silicon Valley, Carti 100 is engineered to revolutionize indoor logistics. Capable of carrying loads up to 220 lbs, and offering extensive customization options, Carti 100 integrates seamlessly into diverse operational envi
Formerra Introduces Formerra+ Upgraded Ecommerce Site to Optimize Customer Experience11.3.2025 09:15:00 CET | Press release
Formerra+™ delivers a faster, smarter, and more seamless way to do business with enhanced product search, intuitive navigation, and powerful management tools. ROMEOVILLE, IL / ACCESS Newswire / March 11, 2025 / Formerra, a leader in performance materials distribution, today launched the Formerra+ ecommerce website, now upgraded to deliver a faster, more intuitive, and personalized experience for customers across multiple industries. The enhanced site provides purchasing, engineering, and quality control customers with easy access to ordering and technical information so that they can get the materials they need faster. "Our customers are looking for efficiency, accuracy, and convenience when managing orders and purchasing materials," said Cathy Dodd, Chief Executive Officer at Formerra. "The upgraded Formerra+ online and mobile experience reflects our commitment to delivering the best digital tools and 24/7 ordering experience to customers worldwide." Formerra+ offers simplified naviga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom